On National HIV Testing Day, getting tested remains a gateway to prevention and treatment, but improving access alone is not enough. Expanding access to PrEP, PEP, pharmacists, long-acting therapies, ...

AML management now hinges on molecularly defined subtypes, supported by numerous targeted approvals; expanding trial access ...

As discussed at a recent IVBM event, Robert Kratzke, MD, outlines essential biomarkers, NGS panel selection, and next steps ...

Recent data from the National Cancer Institute (NCI) suggest that the number of people in the US diagnosed with diffuse large ...

National health spending is forecast to approach $9 trillion by 2034, increasing faster than GDP and consuming 20.6% of the ...

CDC ended the federal response June 24, 2026, after risk diminished, releasing >100 deployed staff from the peak incident ...

Caregivers of patients with CKD report social withdrawal, strained relationships, and stigma, according to a new qualitative ...

Retrospective single-center review of 80 HFrEF patients added SGLT2 inhibitors on stable guideline-directed therapy, with ...

Nipocalimab improved fatigue by week 2 in patients, supporting its potential as a fast-acting, patient-centered therapy, says Irina Murakhovskaya, MD. Since sickle cell disease trial criteria exclude ...

Interrupted time-series signals showed exacerbations increased before 2015 but dropped sharply after 2015 and continued ...

Abnormal creatinine in CKD can justify SGLT2 inhibitor initiation irrespective of diabetes status, given robust renal and ...